2119 Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis. (September 2015) - Franken, M.; Van Rooijen, E.; Van Tinteren, H.; May, A.; Mol, L.; Tije, A. Ten; Creemers, G.J.; Velden, A. Van der; Van derTorren, A.; Groot, C. Uyl-de; Punt, C.; Koopman, M.; et al.